Tevogen Bio Holdings Inc. (TVGN) FY2024 10-K Annual Report
Tevogen Bio Holdings Inc. (TVGN) 10-K annual report for fiscal year 2024, filed with SEC EDGAR on Apr 2, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Tevogen Bio Holdings Inc. FY2024 10-K Analysis
Business Overview
- • Core business: Clinical-stage immunotherapy developing off-the-shelf, precision allogeneic CD8+ T cell therapies for infectious diseases, cancers, and other disorders
- • New emphasis on TVGN 489 for COVID-19 and Long COVID, with Phase 1 proof-of-concept trial completed Jan 2023 and pivotal trial planned for B cell malignancy patients
- • Strategic shift: Completed business combination with Semper Paratus Acquisition Corp in Feb 2024 to become publicly listed as Tevogen Bio Holdings Inc
- • Notable metric: TVGN 489 progressed from pre-discovery to clinic in 18 months, achieving persistence of infused cells for 6 months and no significant adverse events
- • Unique fact: ExacTcell technology delivers off-the-shelf T cell therapies that are not genetically modified, aiming to reduce severe side effects seen in CAR-T platforms
Management Discussion & Analysis
- • Revenue $0, no product sales, consistent with prior year; no expected revenue until product approval and commercialization
- • Net loss $13.7M in 2024 vs $60.5M in 2023; loss from operations $53.6M in 2024 vs $8.8M; operating expenses rose to $53.6M from $8.8M
- • Best performing segment: Change in fair value of convertible promissory notes gain $48.5M in 2024 vs loss $50.4M in 2023; Worst: R&D expenses surged to $31.0M from $4.4M mainly due to stock-based compensation
- • Cash flow: Operating cash outflow $12.0M in 2024 vs $8.2M; Financing inflows $12.3M in 2024 vs $4.0M, including $2.0M Series A, $6.0M Series C preferred stock, $1.0M loan draw; Capex minimal
- • Outlook: Sufficient cash and credit available for 12+ months; plans to expand R&D, manufacturing, commercialization; key risks from clinical development, regulatory approvals, commercialization timing
Risk Factors
- • Regulatory risk: FDA's evolving framework on allogeneic T cell therapy and AI use, with draft guidance increasing compliance costs and potential delays
- • Geopolitical/macro risk: Reliance on $8.0 million grant funding expected Q2 2025 from KRHP LLC critical for liquidity amid no secured additional financing
- • Operational risk: Dependence on procuring consistent, virus-free third-party donor T cells impacting manufacturing reliability and supply chain stability
- • Competitive risk: Novel immunotherapy approach faces risk of market share loss to established and emerging therapies with better clinical trial histories
- • Financial risk: Significant $8.0 million capital need with limited operating history and no commercial products, risking dilution or operational downscaling if additional funding unavailable
Tevogen Bio Holdings Inc. FY2024 Key Financial MetricsXBRL
Net Income
-$14M
▼ -20289.7% YoY
ROE
205.7%
▲ +20530bp YoY
Total Assets
$3M
▼ -79.7% YoY
EPS (Diluted)
$-0.07
▲ +97.1% YoY
Operating Cash Flow
-$12M
▼ -771.8% YoY
Source: XBRL data from Tevogen Bio Holdings Inc. FY2024 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Tevogen Bio Holdings Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.